Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance.
about
Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancerInverse regulation of EGFR/HER1 and HER2-4 in normal and malignant human breast tissue.Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.Disruption of the ER-α36-EGFR/HER2 positive regulatory loops restores tamoxifen sensitivity in tamoxifen resistance breast cancer cellsEGFR signaling in breast cancer: bad to the bone.Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausalCancer stem cells and side population cells in breast cancer and metastasis.In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor αThe ErbB4 CYT2 variant protects EGFR from ligand-induced degradation to enhance cancer cell motility.Downregulation of ER-α36 expression sensitizes HER2 overexpressing breast cancer cells to tamoxifenOptimal structural inference of signaling pathways from unordered and overlapping gene sets.Targeting cholesterol-rich microdomains to circumvent tamoxifen-resistant breast cancer.The development, application and limitations of breast cancer cell lines to study tamoxifen and aromatase inhibitor resistanceSystematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancerUpregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapiesPreclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer.Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration.Does lapatinib work against HER2-negative breast cancers?BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinibExpression of MHC Class I on breast cancer cells correlates inversely with HER2 expressionNew and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus.Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer.Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance.Drug resistance and the role of combination chemotherapy in improving patient outcomes.Targeting BIG3-PHB2 interaction to overcome tamoxifen resistance in breast cancer cells.Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancerTrichostatin A suppresses EGFR expression through induction of microRNA-7 in an HDAC-independent manner in lapatinib-treated cells.Resveratrol fuels HER2 and ERα-positive breast cancer behaving as proteasome inhibitor.Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity?Breast cancer stem cells and their role in resistance to endocrine therapy.Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers.Biomarkers of drugs targeting HER-family signalling in cancer.The novel role of miRNAs for tamoxifen resistance in human breast cancer.Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer.Synergistic disruption of ERα/HER2 crosstalk by endoxifen and lapatinib in breast cancer cells.The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced diseasePhase II study assessing lapatinib added to letrozole in patients with progressive disease under aromatase inhibitor in metastatic breast cancer-Study BES 06.Evolution of Cancer Stem-like Cells in Endocrine-Resistant Metastatic Breast Cancers Is Mediated by Stromal Microvesicles.
P2860
Q27001260-1298DFE8-CA77-4B79-BA0A-A5E610927CFAQ31134061-13C60426-847C-4E1B-92A2-3261EE85AD93Q33648503-02835743-4F4B-4319-AA4F-AEAE3FC770DAQ34156192-02E92A39-5B08-49FA-B1B4-F586664B9554Q34348232-3F57A8E6-5498-4540-AE08-CD0A71AC9FDAQ34611634-A073823C-3405-4D97-A2EA-16EF223B998AQ35038054-9E000324-032C-4125-A3AC-8C45EA0BAC66Q35180278-DF7C28D7-81B3-4EA7-A461-43E3E1E0C43CQ35228445-4DF4163B-A574-463E-8EC7-C87BDA59035FQ35402408-5DE2FB7D-EE4C-4B50-8EC2-E1DEC61A03FCQ35754761-69627699-655C-4488-B8C6-E9B41C363A25Q35889618-99145E9F-74EF-487E-873B-03CEE6C0F152Q36013029-211F3293-BCB4-4962-A1C5-009BB1FD67ABQ36067934-F051E443-157E-4DA0-9BA0-A0B460AC53D7Q36127379-15CA8358-A72A-4BB3-85B3-AF8A6D9741B8Q36245376-569B71A0-F25D-4309-9538-66880D2FFF04Q36245528-1890B81A-6635-4E05-A4E5-E2FB95597002Q36253050-3D68FE58-9A17-4BEB-B56F-740115226A09Q36299102-C785AD5B-21DE-4145-9E4B-939A76D6B7D7Q36388523-7A037FBB-7CF5-4598-AD89-0433F12D21BFQ36547566-691BC1CF-AA83-4F4F-8C97-15ACDA77A409Q36564710-92EE7587-43AA-4F6D-B5BA-3A2433042994Q36589865-410C3D7F-CBC3-44F3-B227-0640F074D503Q36999509-916061A7-918B-4234-9C08-1426212B22C4Q37217695-706A55ED-086F-467D-A266-701947047583Q37356307-6C6ECBF0-F675-4B48-B743-D6B3AA0F687CQ37632279-07E58BB9-3E47-4BEF-8DB0-012CB618B0B6Q37715501-913366A5-F8FC-4F9A-803A-CC89603EEE1AQ37826199-5D582E74-DF4B-4AD4-9BBA-18DAF1712055Q37901429-8AE1C39B-7918-47DA-933F-484AD7ECEAAEQ38004853-E69C21F6-8989-4AE0-8121-C2A6934AF50EQ38150774-EB788088-415F-4AA9-9E29-DC95C6F1E3E1Q38381678-7B4A7335-6455-45B8-89C0-472316F02B4FQ38547729-98107982-8D36-4EDE-89C5-1294FC851BE7Q38726658-15F9FDFC-769F-4343-8168-333078E9719CQ38926422-BD7C338E-CF56-4EBD-86FA-99612BA546DCQ38943401-1F1FD551-9253-41D2-833A-8C21E3229650Q41136265-CD328331-6C6D-4A72-9F69-94D30F756423Q43688694-E7143F8B-3A2B-4028-A22E-5C98611B2014Q46509951-BC57689F-B1B2-44F8-99D7-141E6E62B8BB
P2860
Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Lapatinib restores hormone sen ...... acquired endocrine resistance.
@en
Lapatinib restores hormone sen ...... acquired endocrine resistance.
@nl
type
label
Lapatinib restores hormone sen ...... acquired endocrine resistance.
@en
Lapatinib restores hormone sen ...... acquired endocrine resistance.
@nl
prefLabel
Lapatinib restores hormone sen ...... acquired endocrine resistance.
@en
Lapatinib restores hormone sen ...... acquired endocrine resistance.
@nl
P2093
P1476
Lapatinib restores hormone sen ...... acquired endocrine resistance.
@en
P2093
Alexandra F Leary
Anne E Lykkesfeldt
Lesley-Ann Martin
Simone Detre
Stephen R D Johnston
Sunil Pancholi
Suzanne Drury
P304
P356
10.1158/1078-0432.CCR-09-1764
P407
P577
2010-02-23T00:00:00Z